Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Notice to Our Valued Users

Elsevier has made the difficult decision to close PracticeUpdate permanently. There will be no new content published, effective immediately. Although we are all disappointed by this news, we are incredibly grateful for your engagement and support over the years.

We thank the Editorial Boards, Advisory Boards, and Editorial Contributors for their many years of dedication to educating the healthcare community. Our appreciation extends to the many contributors who have shared their valuable time and expertise to help us parse the latest research over the years.

We encourage you to explore our other offerings such as ScienceDirect and ClinicalKey, which continue to provide valuable insights and information to help you excel in your practice.

If you have any questions or need assistance, please see the FAQs section or contact the support team. Thank you for being a part of the PracticeUpdate community!

Sara M. Tolaney MD, MPH Advisory Board

Oliver Sartor MD Advisory Board

Barbara Burtness MD Advisory Board

See All Experts

Published in Oncology

Journal Scan / Research · March 11, 2024

Humanized Anti–PD-1 Monoclonal Antibody Retifanlimab in Patients With Solid Tumors

ESMO Open

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

Article Citation

ESMO Open

A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)

ESMO Open 2024 Mar 01;9(3)102387, AM Di Giacomo, M Schenker, J Medioni, S Mandziuk, M Majem, G Gravis, M Cornfeld, S Ranganathan, S Lou, T Csoszi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

featured

Final Note From the Oncology Editors

Commentary · January 14, 2025
story of the week

Invasive Disease–Free Survival Outcomes With SLNB vs Omission of Axillary Surgery in Patients With Early-Stage Breast Cancer Treated With Breast-Conserving Surgery

N. Engl. J. Med · December 26, 2024
featured

Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer

N. Engl. J. Med · December 25, 2024
featured

Genomic Instability in Non–Breast or Ovarian Malignancies Among Individuals With Germline Pathogenic Variants in BRCA1/2

J. Natl. Cancer Inst · December 25, 2024
story of the week

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

N. Engl. J. Med · December 24, 2024
featured

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma

Blood · December 24, 2024
featured

Obecabtagene Autoleucel for Adults With B-Cell Acute Lymphoblastic Leukemia

N. Engl. J. Med · December 23, 2024
featured

De-Escalated Neoadjuvant Weekly Nab-Paclitaxel With Trastuzumab and Pertuzumab vs Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab for HER2-Positive Early Breast Cancer

Lancet Oncol · December 19, 2024
story of the week

Blinatumomab in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia

N. Engl. J. Med · December 18, 2024
featured

Tremelimumab and Durvalumab as Neoadjuvant or Non-Operative Management Strategy for Microsatellite Instability–High Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Ann. Oncol · December 17, 2024
story of the week

Efficacy and Safety of Prostate Radiotherapy in Patients With De Novo Metastatic Castration-Sensitive Prostate Cancer

Lancet · December 16, 2024

Notice to Our Valued Users

Humanized Anti–PD-1 Monoclonal Antibody Retifanlimab in Patients With Solid Tumors

Additional Info

A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)

Further Reading

Final Note From the Oncology Editors

Invasive Disease–Free Survival Outcomes With SLNB vs Omission of Axillary Surgery in Patients With Early-Stage Breast Cancer Treated With Breast-Conserving Surgery

Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer

Genomic Instability in Non–Breast or Ovarian Malignancies Among Individuals With Germline Pathogenic Variants in BRCA1/2

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma

Obecabtagene Autoleucel for Adults With B-Cell Acute Lymphoblastic Leukemia

De-Escalated Neoadjuvant Weekly Nab-Paclitaxel With Trastuzumab and Pertuzumab vs Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab for HER2-Positive Early Breast Cancer

Blinatumomab in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia

Tremelimumab and Durvalumab as Neoadjuvant or Non-Operative Management Strategy for Microsatellite Instability–High Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Efficacy and Safety of Prostate Radiotherapy in Patients With De Novo Metastatic Castration-Sensitive Prostate Cancer

Recently Updated